Health-related Quality of Life and Functional Outcomes from a Randomized-withdrawal Study of Long-term Lisdexamfetamine Dimesylate Treatment in Children and Adolescents with ADHD

Friday, October 26, 2012

Liza A. Squires, M.D., Shire Development LLC, Wayne, PA

Tobias Banaschewski, M.D., Ph.D., Department of Child and Adolescent Psychiatry, Mannheim, Germany

Michel Lecendreux, M.D., Pediatric Sleep Center, Hôpital Robert Debré, Paris, France

Mats Johnson, M.D., Child Neuropsychiatry Unit, Göteborg, Sweden

Alessandro Zuddas, M.D., Child Neuropsychiatry, Dept. Neuroscience, University of Cagliari, Cagliari, Italy

Paul Hodgkins, M.S.C., Ph.D., Shire Development LLC, Wayne, PA

Ralph Bloomfield, MSC, Shire Pharmaceuticals, Inc., Basingstoke, United Kingdom

David Coghill, M.D., F.R.C.Psych., MBChB, Division of Neuroscience, Ninewells Hospital, Dundee, Scotland